FDA Approval Alert: The Need-to-Know | Isatuximab/VRd in Transplant-Ineligible NDMM

In September 2024, the FDA approved isatuximab-irfc plus bortezomib, lenalidomide, and dexamethasone (Isa-VRd) as a treatment for patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant.

Thomas G. Martin, MD, discussed the advantages of quadruplet therapy for multiple myeloma in light of an FDA approval for Isa-VRd in this indication.

Quadruplet Therapy Shows Benefit for Newly Diagnosed Multiple Myeloma

Article

By Roman Fabbricatore

Oct 4, 2024 8:00 PM

Thomas G. Martin, MD, discussed the advantages of quadruplet therapy for multiple myeloma in light of an FDA approval for Isa-VRd in this indication.

Adding bortezomib to Isa-Rd triplet therapy enhanced MRD-negative responses in patients with transplant-ineligible multiple myeloma.

Adding Bortezomib to Isa-Rd Elicits Durable Responses for Multiple Myeloma

Video

By Thomas G. Martin, MD

Oct 3, 2024 12:00 PM

Adding bortezomib to Isa-Rd triplet therapy enhanced MRD-negative responses in patients with transplant-ineligible multiple myeloma.

Isatuximab plus VRd triplet therapy did not significantly increase toxicity in patients with transplant-ineligible multiple myeloma in the IMROZ trial.

Isatuximab Quadruplet Therapy Appears Well Tolerated in Multiple Myeloma

Video

By Thomas G. Martin, MD

Oct 2, 2024 8:00 PM

Isatuximab plus VRd triplet therapy did not significantly increase toxicity in patients with transplant-ineligible multiple myeloma in the IMROZ trial.